Onconephrology patients share a common feature: decreased survival. This is where Palliative Care finds a role in managing for these patients. However, during the course of illness and its treatment, providers often overlook the importance of assessing prognosis, predicting disease trajectory, and addressing goals of care discussions with patients and their family. Knowing which factors portend a poor outcome in this population helps bind together the subspecialties of Oncology, Nephrology and Palliative Care and frame interventions within patients’ treatment goals. As the life expectancies of patients suffering from cancer and kidney disease is short, knowledge of these foreboding factors helps initiate end of life planning which has shown to be beneficial for our patients’ quality of life.
CampbellGAHuDOkusaMD.Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis2014; 21(1): 64–71.
3.
SalahudeenAKDoshiSMPawarT, et al. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol2013; 8(3): 347–354.
4.
JinJWangYShenQ, et al. Acute kidney injury in cancer patients: a nationwide survey in China. Sci Rep2019; 9(1): 3540.
5.
SoaresMFontesFDantasJ, et al. Performance of six severity-of-illness scores in cancer patients requiring admission to the intensive care unit: a prospective observational study. Crit Care2004; 8: R194.
6.
LameireNVanholderRVan BiesenW, et al. Acute kidney injury in critically ill cancer patients: an update. Crit Care2016; 20: 209.
7.
KangEParkMParkPG, et al. Acute kidney injury predicts all-cause mortality in patients with cancer. Cancer Med2019; 8(6): 2740–2750.
8.
RosnerMHPerazellaMA.Acute kidney injury in the patient with cancer. Kidney Res Clin Pract2019; 38(3): 295–308.
9.
ChristiansenCFJohansenMBLangebergWJ, et al. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med2011; 22(4): 399–406.
10.
LahotiAKantarjianHSalahudeenAK, et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer2010; 116(17): 4063–4068.
11.
DarmonMVincentFCanetE, et al. Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie. Nephrol Dial Transplant2015; 30(12): 2006–2013.
12.
SoaresMSalluhJICarvalhoMS, et al. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol2006; 24: 4003–4010.
13.
GrussEBernisCTomasJF, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol1995; 15: 473–479.
14.
ChuvaTMaximinoJBarbosaJ, et al. Haematological malignancies and acute kidney injury requiring nephrology consultation: challenging the worst of the worst. Clin Kidney J2016; 9(3): 418–423.
15.
VakitiAPadalaSAMewawallaP.Myeloma kidney. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, https://www.ncbi.nlm.nih.gov/books/NBK499952/ (2020, accessed 27 June 2020).
16.
AlexanianRBarlogieBDixonD.Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med1990; 150: 1693–1695.
17.
LamAQHumphreysBD.Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol2012; 7(10): 1692–1700.
18.
ChowCCMoKLChanCK, et al. Renal impairment in patients with multiple myeloma. Hong Kong Med J2003; 9(2): 78–82.
RodriguesLNevesMSaH, et al. Severe acute kidney injury and multiple myeloma: evaluation of kidney and patient prognostic factors. Eur J Intern Med2014; 25(7): 652–656.
21.
DimopoulosMARichardsonPGSchlagR, et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol2009; 27: 6086–6093.
22.
DimopoulosMARoussouMGavriatopoulouM, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol2016; 91: 499–502.
23.
HaynesRJReadSCollinsGP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant2010; 25(2): 419–426.
24.
BladéJFernández-LlamaPBoschF, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med1998; 158(17): 1889–1893.
25.
HutchisonCACockwellPReidS, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol2007; 18: 886–895.
26.
LicataAMaidaMBonaccorsoA, et al. Clinical course and prognostic factors of hepatorenal syndrome: a retrospective single-center cohort study. World J Hepatol2013; 5(12): 685–691.
27.
BelcherJMGarcia-TsaoGSanyalAJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology2013; 57(2): 753–762.
28.
LimCAudureauESalloumC, et al. Acute kidney injury following hepatectomy for hepatocellular carcinoma: incidence, risk factors and prognostic value. HPB (Oxford)2016; 18(6): 540–548.
29.
BressanAKJamesMTDixonE, et al. Acute kidney injury following resection of hepatocellular carcinoma: prognostic value of the acute kidney injury network criteria. Can J Surg2018; 61(5): E11–E16.
30.
ZhouCWangRDingY, et al. Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma. Int J Clin Exp Pathol2014; 7(5): 2579–2586.
31.
PatelKFosterNRKumarA, et al. Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival. Support Care Cancer2015; 23(5): 1303–1309.
32.
EmmertCRasslerJKöhlerU.Survival and quality of life after percutaneous nephrostomy for malignant ureteric obstruction in patients with terminal cervical cancer. Arch Gynecol Obstet1997; 259(3): 147–151.
33.
HarringtonKJPandhaHSKellySA, et al. Palliation of obstructive nephropathy due to malignancy. Br J Urol1995; 76(1): 101–107.
34.
SouzaACPSouzaANKirsztajnR, et al. Cervical cancer: renal complications and survival after percutaneous nephrostomy. Rev Assoc Med Bras2016; 62(3): 255–261.
KitchluAMcArthurEAmirE, et al. Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study. J Natl Cancer Inst2019; 111(7): 727–736.
SilverSAHarelZMcArthurE, et al. Causes of death after a hospitalization with AKI. J Am Soc Nephrol2018; 29(3): 1001–1010.
39.
JhaveriKDWanchooRSakhiyaV, et al. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep2016; 2(1): 108–123.
Ñamendys-SilvaSAArredondo-ArmentaJMPlata-MenchacaEP, et al. Tumor lysis syndrome in the emergency department: challenges and solutions. Open Access Emerg Med2015; 7: 39–44.
42.
ReillyRJr.Calcium and phosphorus disorders. Onco-Nephrology, Elsevier, 2020.
43.
DarmonMGuichardIVincentF, et al. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma2010; 51(2): 221–227.
44.
DuraniUShahNDGoRS.In-hospital outcomes of tumor lysis syndrome: a population-based study using the national inpatient sample. Oncologist2017; 22(12): 1506–1509.
45.
IzzedineHPerazellaMA.Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis2015; 66(5): 857–868.
CanetEVincentFDarmonM, et al. Acute kidney injury in hematological patients. Curr Opin Crit Care2015; 21(6): 549–558.
48.
BenoitDDHosteEADepuydtPO, et al. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant2005; 20: 552–558.
49.
CanetEZafraniLLambertJ, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One2013; 8(2): e55870.
50.
HavrileskyLJReinerMMorrowPK, et al. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol2015; 93(3): 203–210.
51.
FauciJMWhitworthJMSchneiderKE, et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol2011; 122(3): 532–535.
52.
BanderaEVLeeVSRodriguez-RodriguezL, et al. Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. JAMA Oncol2015; 1(6): 737–745.
53.
VeitchZKhanOFTilleyD, et al. Impact of cumulative chemotherapy dose on survival With adjuvant FEC-D chemotherapy for breast cancer. J Natl Compr Canc Netw2019; 17(8): 957–967.
54.
MerchanJJhaveriK. Chemotherapy nephrotoxicity and dose modification in patients with kidney impairment: conventional cytotoxic agents. In: DrewsRBernsJ (ed.) UpToDate. Waltham, MA: UpToDate.
55.
HorieSOyaMNangakuM, et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol2018; 22(1): 210–244.
56.
de JonghFEvan VeenRNVeltmanSJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer2003; 88(8): 1199–1206.
57.
PerazellaMASprangersB.AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol2019; 14(7): 1077–1079.
ClajusCHankeNGottliebJ, et al. Renal comorbidity after solid organ and stem cell transplantation. Am J Transplant2012; 12(7): 1691–1699.
61.
KrishnappaVGuptaMManuG, et al. Acute kidney injury in hematopoietic stem cell transplantation: a review. Int J Nephrol2016; 2016: 5163789.
62.
LopesJAJorgeS.Acute kidney injury following HCT: incidence, risk factors and outcome. Bone Marrow Transplant2011; 46: 1399–1408.
63.
MerouaniAShpallEJJonesRB, et al. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int1996; 50: 1026–1031.
64.
KlineJSubbiahSLazarusH, et al. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant2008; 41: 505–513.
65.
SehgalBGeorgePJohnMJ, et al. Acute kidney injury and mortality in hematopoietic stem cell transplantation: a single-center experience. Indian J Nephrol2017; 27(1): 13–19.
66.
ParikhCRMcSweeneyPAKorularD, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int2002; 62(2): 566–573.
McDonaldGBHindsMSFisherLD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med1993; 118: 255–267.
69.
RosolemMMRabelloLSLisboaT, et al. Critically ill patients with cancer and sepsis: clinical course and prognostic factors. J Crit Care2012; 27(3): 301–307.
70.
HumphreysBDSoifferRJMageeCC.Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol2005; 16(1): 151–161.
71.
LanoreJJBrunetFPochardF, et al. Hemodialysis for acute renal failure in patients with hematologic malignancies. Crit Care Med1991; 19(3): 346–351.
72.
LiYChenXShenZ, et al. Electrolyte and acid-base disorders in cancer patients and its impact on clinical outcomes: evidence from a real-world study in China. Ren Fail2020; 42(1): 234–243.
73.
MilionisHJBourantasCLSiamopoulosKC, et al. Acid-base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol1999; 62(4): 201–207.
74.
HowardSCJonesDPPuiCH.The tumor lysis syndrome [published correction appears in N Engl J Med 2018; 379(11): 1094]. N Engl J Med2011; 364(19): 1844–1854.
75.
MontfordJRLinasS.How dangerous is hyperkalemia?J Am Soc Nephrol2017; 28(11): 3155–3165.
WeeksJCCookEFO’DaySJ, et al. Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA1998; 279: 1709–1714.
78.
RamosREOPerez MakMAlvesMFS, et al. Malignancy-related hypercalcemia in advanced solid tumors: survival outcomes. J Glob Oncol2017; 3(6): 728–733.
79.
DoshiSMShahPLeiX, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis2012; 59: 222–228.
80.
VermaAQayyumR.Anion gap and cancer mortality: insight from NHANES database. J Clin Oncol2017; 35(15_suppl): e13068.
81.
LowranceWTOrdoñezJUdaltsovaN, et al. CKD and the risk of incident cancer. J Am Soc Nephrol2014; 25(10): 2327–2334.
82.
ButlerAMOlshanAFKshirsagarAV, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis2015; 65(5): 763–772.
83.
HeafJGHansenALaierGH.Quantification of cancer risk in glomerulonephritis. BMC Nephrol2018; 19(1): 27.
84.
ChertowGMPaltielADOwenWFJr, et al. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med1996; 156(12): 1345–1350.
85.
MalyszkoJTesarovaPCapassoG, et al. The link between kidney disease and cancer: complications and treatment. The Lancet2020; 396: 277–287.
86.
JhambMAbdel-KaderKYabesJ, et al. Comparison of fatigue, pain, and depression in patients with advanced kidney disease and cancer-symptom burden and clusters. J Pain Symptom Manage2019; 57(3): 566–575.e3.
87.
PedrazzoliPSilvestrisNSantoroA, et al. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). ESMO Open2017; 2(3): e000167.
88.
NaSYSungJYChangJH, et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol2011; 33: 121–130.
89.
WengPHHungKYHuangHL, et al. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol2011; 6(5): 1121–1128.
90.
KrensSDLasscheGJansmanFGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol2019; 20(4): e200–e207.
91.
KitchluAShapiroJAmirE, et al. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA2018; 319(23): 2437–2439.
92.
KuoJCCraftPS.Administration of chemotherapy in patients on dialysis. Anticancer Drugs2015; 26(7): 779–784.
93.
JanusNLaunay-VacherVThyssA, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol2013; 24(2): 501–507.
94.
GhandourhWA.Palliative care in cancer: managing patients’ expectations. J Med Radiat Sci2016; 63(4): 242–257.
95.
LiuPHLandrumMBWeeksJC, et al. Physicians’ propensity to discuss prognosis is associated with patients’ awareness of prognosis for metastatic cancers. J Palliat Med2014; 17(6): 673–682.
96.
HeylandDKAllanDERockerG, et al. Discussing prognosis with patients and their families near the end of life: impact on satisfaction with end-of-life care. Open Med2009; 3: 101–110.
97.
ChuCWhiteNStoneP.Prognostication in palliative care. Clin Med (Lond)2019; 19(4): 306–310.
98.
WrightAAZhangBRayA, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA2008; 300: 1665–1673.
99.
MackJWWolfeJCookEF, et al. Hope and prognostic disclosure. J Clin Oncol2007; 25: 5636–5642.
100.
HottensenD.Anticipatory grief in patients with cancer. Clin J Oncol Nurs2010; 14: 106–107.
101.
MittmannNLiuNMacKinnonM, et al. Does early palliative identification improve the use of palliative care services?PLoS One2020; 15(1): e0226597.
